HeartBeam (BEAT) announced that the FDA has granted 510(k) clearance for the company’s 12-lead electrocardiogram synthesis software for the assessment of arrhythmias. This clearance follows HeartBeam’s successful appeal of a prior Not Substantially Equivalent determination.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BEAT:
- HeartBeam initiated with a Buy at H.C. Wainwright
- HeartBeam (NASDAQ: BEAT) Outlines Regulatory Strategy After NSE Decision on ECG Synthesis Software
- HeartBeam’s Strategic Path to Overcome Regulatory Challenges and Secure Buy Rating
- HeartBeam updates regulatory strategy for 12-lead ECG Synthesis Software
- Roth sees potential FDA clearance for HeartBeam despite letter